🔗 Share this article

As the United States proceeds with unprecedented changes to its vaccine schedules, an unexpected name has emerged in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports physician and public health researcher who first made her name by expressing skepticism about Covid vaccines in the global health crisis and has focused upon alleged fatalities after Covid vaccination in her short tenure at the Food and Drug Administration.

Proposed Changes to Pediatric Vaccine Program

Agency leaders planned to announce sweeping revisions to the pediatric immunization program earlier this month, aligning the US with Denmark’s national calendar, sources say – a major change that would place the US out of alignment with much of the global community with insufficient data for public health gain. The planned update has been postponed until the new year.

Instead of Vinay Prasad, Dr. Høeg is listed to present at the event. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth appointee to lead the center this calendar year.

A Shift at the Agency

Høeg's temporary position may indicate a tighter collaboration between the drug and biologics centers as Høeg and Dr. Prasad solidify control at the regulatory agency – and it points to a increased emphasis upon dismantling long-standing vaccines at the FDA.

The new acting director has often pushed for discontinuing certain pediatric vaccine recommendations in the US to become more like Denmark, a country with universal health coverage and a population about the size of Wisconsin’s.

So far comments, she has persisted in emphasizing on immunizations – typically the domain of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Concerns Over Expertise

The appointee has little discernible background in drug development, approval processes or management, which has been typical for previous leaders of the biologics center. She has been employed at the FDA as a key advisor to the FDA chief and the vaccine center since March.

“She appears not to have any of the qualifications” for leading the drug-regulation department, remarked Dr. Jonathan Howard. “She’s never run a randomized controlled trial. She lacks experience in running a major agency. She has no expertise in pharmaceutical oversight.”

Past directors of CBER would “understand regulatory frameworks and the science of drug development”, commented a former acting FDA commissioner. “Clearly, she has not acquired the sort of resume that prior appointees who led the center have had.”

CDER has an enormous range of responsibilities at the agency, she stated.

“Everybody just focuses on the novel medication approvals, but the generic program approves numerous off-brand pharmaceuticals. There’s a biologic copycat branch, non-prescription drug unit and so forth, and every single one need to be supervised,” Dr. Woodcock noted. “The area you overlook, that is the part that I always told people is going to cause problems.”

Additionally, a significant management element to the position, which manages in excess of 5,000 personnel. “It’s a enormous leadership role, if you do it right,” she added.

Agency Reaction and Contentious Policies

Regarding concerns about Dr. Høeg's fitness for the role and whether this appointment represents increased cooperation among FDA leaders on immunizations, a representative said that the “questions stem from flawed presumptions”.

“This background aligns with the duties of her job,” the spokesperson explained, citing the months Høeg spent guiding the FDA commissioner on “drug safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As acting director, Høeg assumes responsibility for the commissioner’s new priority voucher program, a disputed expedited drug-approval program that reportedly troubled her former heads. “By what process are these drugs being selected for this fast-track system? Who takes the decisions?” Howard asked. “There’s a lot of lack of transparency going on at the FDA right now.”

In general, he stated, “the agency looks to be trending towards laxer oversight of pharmaceuticals, with the exception of shots.”

Documented Track Record on Vaccines

With vaccines, Høeg has a more documented, if troubling, past, critics said. She released a study using unverified public submissions to determine the frequency of heart inflammation following Covid vaccination. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who was said to have changed statistics to imply Covid vaccinations are more dangerous than they are.

Included in her “wish list” for the current administration featured altering guidelines for novel immunizations and discontinuing “unnecessary” vaccines, she said following the vote on a online show. At the agency, Høeg has allegedly proposed excluding teenage boys from getting Covid vaccines.

“She’s an all-around true believer who commences with her conclusions and reverse-engineers to retrofit the science in a extremely misleading, untruthful way,” Dr. Howard stated.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg aligned with fellow contrarians, {like|